All coverage
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
By Annika Kim Constantino
Experimental Alzheimer's drug donanemab outperforms Leqembi in clinical trial : Shots - Health News
By Jon Hamilton
Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety risk
By Lauran Neergaard
Drug donanemab seen as turning point in dementia fight
By Fergus Walsh & Michelle Roberts
Alzheimer's trial shows clear benefits and significant risks of Eli Lilly antibody
By Jennifer Couzin
New class of Alzheimer's drugs showing promise in patients in early stage of disease
By Alison Branley
Eli Lilly’s Alzheimer’s drug slows memory decline, study finds
By Berkeley Lovelace & Berkeley Lovelace Jr.
Second Alzheimer’s drug to slow disease’s progression may be approved in the US this year
By Meg Tirrell
Eli Lilly's experimental Alzheimer's drug slows disease, data show
By Laurie McGinley